283 related articles for article (PubMed ID: 31179583)
1. Acute myeloid leukemia drug development in the post-venetoclax era.
Pollyea DA
Am J Hematol; 2019 Sep; 94(9):959-962. PubMed ID: 31179583
[No Abstract] [Full Text] [Related]
2. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Aldoss I; Marcucci G
Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
[No Abstract] [Full Text] [Related]
3. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
4. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
5. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
[No Abstract] [Full Text] [Related]
6. [Application of Bcl-2 inhibitor venetoclax in acute myeloid leukemia].
Zhang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):438-440. PubMed ID: 34218592
[No Abstract] [Full Text] [Related]
7. Venetoclax for Refractory Myeloid Sarcoma.
Kanate AS; Vos J; Chargualaf MJ
J Oncol Pract; 2019 Jul; 15(7):413-415. PubMed ID: 31291562
[No Abstract] [Full Text] [Related]
8. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Maiti A; DiNardo CD; Daver NG; Rausch CR; Ravandi F; Kadia TM; Pemmaraju N; Borthakur G; Bose P; Issa GC; Short NJ; Yilmaz M; Montalban-Bravo G; Ferrajoli A; Jabbour EJ; Jain N; Ohanian M; Takahashi K; Thompson PA; Loghavi S; Montalbano KS; Pierce S; Wierda WG; Kantarjian HM; Konopleva MY
Blood Cancer J; 2021 Feb; 11(2):25. PubMed ID: 33563904
[No Abstract] [Full Text] [Related]
9. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax in AML: Where We Are and Where We Are Headed.
Pollyea DA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agents with venetoclax: have we discovered the holy grail?
Gutman JA; Pollyea DA
Curr Opin Hematol; 2020 Mar; 27(2):76-80. PubMed ID: 31895103
[TBL] [Abstract][Full Text] [Related]
12. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
13. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
14. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
15. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
[No Abstract] [Full Text] [Related]
16. [Venetoclax combined with hypomethylating agents induced tumor lysis syndrome in patients with acute leukemia: 7 cases report and literature review].
Guo YS; Zhao CH; Hu DY; Shen K; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):508-511. PubMed ID: 37550210
[No Abstract] [Full Text] [Related]
17. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
[No Abstract] [Full Text] [Related]
18. Can we selectively target AML stem cells?
Jordan CT
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax in acute myeloid leukemia.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Investig Drugs; 2023 Apr; 32(4):271-276. PubMed ID: 36933006
[No Abstract] [Full Text] [Related]
20. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement.
Otoukesh S; Zhang J; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V; Aldoss I
Leuk Lymphoma; 2020 Aug; 61(8):2020-2023. PubMed ID: 32191144
[No Abstract] [Full Text] [Related]
[Next] [New Search]